Decreased expression of c-MPL protein in platelets, increased expression of PRV-1 and NFIB mRNA in granulocytes and loss of heterozygosity on chromosome 9p (9pLOH) were described as molecular markers for myeloproliferative disorders (MPD). To assess whether these markers are clustered in subgroups of MPD or represent independent phenotypic variations, we simultaneously determined their status in a cohort of MPD patients. Growth of erythropoietin-independent colonies (EEC) was measured for comparison. We observed concordance between EEC and PRV-1 in MPD patients across all diagnostic subclasses, but our results indicate that EEC remain the most reliable auxiliary test for polycythemia vera (PV). In contrast, c-MPL, NFIB and 9pLOH constitute independent variations. Interestingly, decreased c-MPL and elevated PRV-1 were also observed in patients with hereditary thrombocythemia (HT) who carry a mutation in the thrombopoietin (TPO) gene. Thus, altered c-MPL and PRV-1 expression can also arise through a molecular mechanism different from sporadic MPD.
Introduction
Previous reports suggested that decreased expression of c-MPL protein in platelets and elevated expression of PRV-1 mRNA in granulocytes is a characteristic feature of patients with PV. 1, 2 These findings raised hopes that assessing expression of c-MPL and PRV-1 may replace the need for determining the growth of EECs, a valuable, but technically demanding assay for PV. [3] [4] [5] Since low c-MPL and high PRV-1 were also detected in some patients with essential thrombocythemia (ET) and chronic idiopathic myelofibrosis (IMF), 1,2,6-8 these markers might define subsets within these MPD entities.
Recently, 9pLOH was described as the most frequent chromosomal aberration in PV patients and increased expression of mRNA for the transcription factor NFIB was found in some patients with 9pLOH. 9 To determine whether these markers constitute independent phenotypic variations or appear clustered in subgroups of MPD patients we simultaneously determined the c-MPL, PRV-1, EEC, NFIB and 9pLOH status in a cohort of 44 MPD patients and 18 normal control individuals.
Patients, Materials and Methods

Study design
The study was approved by the local ethics committee. Blood was obtained with written consent. The diagnosis of MPD subtypes was assigned using the WHO criteria.
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Protein, RNA and DNA analyses
All blood samples were processed within 1-4 hours after drawing. Isolation of granulocyte RNA and DNA was described elsewhere. 9 RNA integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, Ca). Platelets were purified using the Sepharose gel-filtration method. 11 c-MPL protein expression was determined by immunoblot analysis using the polyclonal rabbit antibody (CTP7) specific for the C-terminus of human c-MPL (kindly provided by Dr. A. Moliterno and Dr. J.
Spivak, Johns Hopkins University, Baltimore). To normalize for platelet protein loading, the membranes were reprobed using a monoclonal antibody against human CD61 (BD Biosciences, San Jose, CA). TPO serum levels were determined using the TPOQuantikine ELISA (R&D Systems, Minneapolis, MN).
Real-time PCR.
Total RNA (2 µg) was reverse transcribed after random hexamer priming. To prevent influence from genomic DNA amplification, the primers for RPL19, PRV-1, and NFIB were designed across exon-intron junctions. The primers for RPL19 were: 12 All reactions were run in duplicate using the ABI 7000 Sequence Detection System (Applied Biosystems, Foster City, CA).
EEC assay
The clonogenic cultures for EPO-independent colony formation (EEC assay) were performed using commercial reagents (Stem Cell Laboratories, Vancouver, BC).
Detection of 9pLOH.
Three highly polymorphic microsatellite markers D9S1779, D9S157, and D9S161 were used to detect LOH in granulocyte DNA samples as described.
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Results and discussion
To determine whether alterations in platelet c-MPL protein expression, granulocyte PRV-1 and NFIB mRNA levels, growth of EECs and the presence of 9pLOH represent independent phenotypic variations, we examined 44 patients with MPD (23 PV, 15 ET,
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From and 6 IMF) ( Figure 1A ). As controls, 18 normal individuals were included ( Figure 1B ).
Decreased expression of c-MPL protein was found in 30% of patients with PV (7/23), 40% of ET (6/15) and 67% of IMF (4/6). Thus, c-MPL cannot be used as a diagnostic test for PV. To assess whether lower expression of c-MPL is specific for MPD, we examined a family with hereditary thrombocythemia (HT). In this family, thrombocytosis is caused by elevated TPO serum levels due to a splice donor mutation in the TPO gene. 13 We Importantly, EECs were negative in all affected family members ( Figure 1C ). Thus, EECs remain the most reliable auxiliary diagnostic assay for PV.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Loss of heterozygosity on the short arm of chromosome 9 (9pLOH) was recently reported to be the most frequent genetic lesion in PV, affecting approximately 30% of PV patients. 9 In comparison, deletion of 20q and various chromosome 9 aberrations were previously reported in 15% and 21% of PV patients, respectively. 15, 16 In our present study, 7 of 23 PV patients (30%) displayed 9pLOH, confirming the previously observed 9pLOH frequency. The 9pLOH was also present in one patient with ET. Interestingly, all 8 individuals with 9pLOH were EEC positive and also displayed elevated PRV-1.
Expression of NFIB was hypothesized to be a consequence of 9pLOH. 9 Our study detected increased NFIB expression in 8 MPD patients with EEC (5 PV, 1 ET and 2 IMF), but, none of these individuals had 9pLOH, indicating that increased expression of the NFIB gene is independent of the presence of 9pLOH. The correlation between 9pLOH and increased NFIB in the original report was most likely a coincidence within a small cohort of 3 patients. No increase in NFIB mRNA was noted in HT family members ( Figure 1C ).
The concordance between EEC and PRV-1 markers in MPD patients across all diagnostic subclasses suggests that they might be caused by a common molecular mechanism. In contrast, decreased expression of c-MPL appears to be an independent phenotypic variant. Interestingly, low c-MPL and high PRV-1 can also occur secondary to elevated TPO in patients with HT. Increased NFIB expression and presence of 9pLOH are independent of each other, but were detected only in patients with EEC and/or high PRV-1. Larger cohort studies will be necessary to determine whether MPD subgroups defined by these molecular markers differ in respect to clinical outcome, e.g. leukemic transformation or hemorrhagic and thrombotic complications. 3 E E E P P P E P P P P P P P P P P P P P P P P E P M E P E P P E E E 
